Psilocybin-Biosynthesis on Bioeconhttps://en.bioecon.ru/technologies/psilocybin-biosynthesis/Recent content in Psilocybin-Biosynthesis on BioeconHugoen-USSat, 04 Jul 2026 22:52:18 +0700Psychedelic medicine & neuropsychiatric biologicshttps://en.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/Sat, 04 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/Psychoactive-compound therapies (psilocybin, MDMA, 5-MeO-DMT) and next-generation non-hallucinogenic psychoplastogens that trigger rapid synaptogenesis via serotonin 5-HT2A receptor signaling, targeting treatment-resistant depression and PTSD — a field with genuine 2026 clinical wins and a high-profile FDA regulatory setback.